Skip to content

Surgical Management of Cerebral Arteriovenous Malformations Within Hybrid Operation Room

Surgical Management of Cerebral Arteriovenous Malformations Within Hybrid Operation Room

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03209804
Acronym
SMAVMHR
Enrollment
519
Registered
2017-07-06
Start date
2016-06-30
Completion date
2020-01-16
Last updated
2020-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Arteriovenous Malformations

Keywords

Intracranial Arteriovenous Malformations

Brief summary

To evaluate the clinical benefits and risks of hybrid operating techniques in management of cerebral arteriovenous malformations.

Detailed description

Purpose: Have an evaluation of clinical benefits and risks of hybrid operating techniques in management of cerebral arteriovenous malformations(AVMs). Meanwhile, as a new cooperative interventional modality, optimized workflows, technical key knots and operation routines will be explored in the study. Objects: Patients with cerebral arteriovenous malformations, coincident with inclusion and exclusion criterion and admitted in participating organizations. Methods: Patients will be distributed into 2 groups, including traditional therapy group(control group) and hybrid operating group(trial group), and conduct with traditional neurosurgical management or one-stage hybrid operating management correspondingly. Residual rate of AVM is considered to be the primary observing indicator, and morbidity rate of post-operative complications, post-operative mortality rate, and morbidity rate of neural functional deterioration are secondary indicators.The information of operations will be recorded in detail as evidence of optimization of workflow and technical key knots.

Interventions

A one-stage cooperation of existing endovascular interventional techniques and microsurgical techniques, including microsurgical resection, endovascular embolization, balloon occlusion.

Sponsors

Beijing Municipal Science & Technology Commission
CollaboratorOTHER
Ministry of Science and Technology of the People´s Republic of China
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Traditional therapy group:traditional management of AVMs, such as unsimultaneous endovascular interventional embolisation, radiotherapy followed by microsurgical resection, will be conducted to patients involved in this group. Hybrid operation group: A one-stage hybrid operation combining endovascular intervention and microsurgical techniques will be conducted simultaneously to patients in this group.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* newly ruptured AVM with stable hematoma, selective operation is practical; * with rupture history; * recurrent epilepsy, failed in AED management; * giant AVM with deterioration of neurological functions; * 1-4 grade AVM (Spetzler-Martin grading system) with no symptom and not located in eloquent area.

Exclusion criteria

* \>70 in age, with low rupture risk; * newly ruptured AVM with unstable hematoma, engaged in emergency operation; * ≥5 grade in Spetzler-Martin grading system; * AVM located in hypothalamus, brainstem, cerebellopontine angle; * cannot tolerant the operation; * patient or relative refuses to participate the trail.

Design outcomes

Primary

MeasureTime frameDescription
Instant residual rate of AVMsup to 1 week after operationThe instant post-operative residual rate of AVMs
3 months' residual rate of AVMsthe date of 3rd month after operation, ±1 week3 months' residual rate after AVM operation
6 months' residual rate of AVMsthe date of the 6th month after operation, ±1 week6 months' residual rate after AVM operation
1 year's residual rate of AVMsthe date of the 12th month after operation, ±1 week1 year's residual rate after AVM operation

Secondary

MeasureTime frameDescription
Morbidity rate of neural functional deterioration-3 months after operationthe 3rd month after operation, ±1 weekThe score of modified Rankin Scale increases ≥2
Morbidity rate of post-operative complications7 days after operationInclude intracranial hemorrhage or infarction, infection of central neural system, infection of respiratory system, cranial nerve deficits, and other symptomatic complications
Morbidity rate of neural functional deterioration-12 months after operationthe 12th month after operation, ±1 weekThe score of modified Rankin Scale increases ≥2
Morbidity rate of neural functional deterioration-6 months after operationthe 6th month after operation, ±1 weekThe score of modified Rankin Scale increases ≥2
Post-operative mortality rate48 hours after operationoperation related mortality
Morbidity rate of neural functional deterioration-48 hours after operationthe assessing time points is 48 hours after operationThe score of modified Rankin Scale increases ≥2
Morbidity rate of neural functional deterioration-1 week after operation1 week after operationThe score of modified Rankin Scale increases ≥2

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026